Inactive Instrument

Analyst Reco. Iovance Biotherapeutics Inc Nasdaq

Equities

US53619R1023

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

Piper Sandler Adjusts Iovance Biotherapeutics Price Target to $19 From $18, Maintains Overweight Rating	Mar. 14	MT
Wells Fargo Adjusts Price Target on Iovance Biotherapeutics to $25 From $22, Maintains Overweight Rating	Mar. 01	MT
Barclays Raises Price Target on Iovance Biotherapeutics to $22 From $18, Maintains Overweight Rating	Feb. 29	MT
Goldman Sachs Raises Price Target on Iovance Biotherapeutics to $19 From $13, Maintains Buy Rating	Feb. 20	MT
Piper Sandler Adjusts Price Target on Iovance Biotherapeutics to $18 From $14, Maintains Overweight Rating	Feb. 20	MT
Dwindling Rate Cut Hopes Push Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday	Feb. 20	MT
Chardan Boosts Price Target on Iovance Biotherapeutics to $34 From $29, Keeps Buy Rating	Feb. 20	MT
HC Wainwright Cuts Price Target on Iovance Biotherapeutics to $28 From $38, Maintains Buy Rating	Nov. 08	MT
Barclays Cuts Price Target on Iovance Biotherapeutics to $18 From $40, Maintains Overweight Rating	23-09-18	MT
Stifel Nicolaus Adjusts Iovance Biotherapeutics Price Target to $25 From $27, Maintains Buy Rating	23-09-13	MT
Wells Fargo Upgrades Iovance Biotherapeutics to Overweight From Equalweight, Raises Price Target to $17 From $11	23-05-30	MT
Stifel Adjusts Price Target on Iovance Biotherapeutics to $24 From $21, Maintains Buy Rating	23-05-30	MT
Baird Adjusts Iovance Biotherapeutics Price Target to $23 From $20, Maintains Outperform Rating	23-05-23	MT
Baird Adjusts Price Target on Iovance Biotherapeutics to $20 From $25, Maintains Outperform Rating	23-05-10	MT
Wells Fargo Adjusts Price Target on Iovance Biotherapeutics to $11 From $14, Maintains Equal-Weight Rating	23-03-06	MT
Oppenheimer Adjusts Iovance Biotherapeutics' Price Target to $15 From $25, Maintains Outperform Rating	23-03-01	MT
Piper Sandler Upgrades Iovance Biotherapeutics to Overweight From Neutral, Adjusts Price Target to $14 From $11	23-01-27	MT
Truist Securities Adjusts Iovance Biotherapeutics' Price Target to $17 From $16, Keeps Buy Rating	23-01-24	MT
Goldman Sachs Downgrades Iovance Biotherapeutics to Neutral From Buy, Adjusts Price Target to $6 From $20	22-12-09	MT
JMP Securities Lowers Price Target on Iovance Biotherapeutics to $21 From $25, Maintains Market Outperform Rating	22-11-21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Iovance Biotherapeutics Inc Nasdaq

Equities

US53619R1023

Analyst Reco.

Filters